Health Canada MDEL Phase 2: Foreign Distributor Exemption, Supplier Lists & GUI-0016
Operating guide to Health Canada MDEL Phase 2 (SOR/2026-110, GUI-0016 Dec 14 2026): keep-or-cancel, supplier lists, procedures, and CAD $5,519.
Health Canada has finalized Phase 2 of its Medical Device Establishment Licence (MDEL) modernization. The legal instrument is SOR/2026-110 (Regulations Amending the Medical Devices Regulations (Establishment Licences)), registered June 4, 2026 (P.C. 2026-550) and published in the Canada Gazette, Part II, Volume 160, Number 12 on June 17, 2026. It rewrites who must hold an establishment licence, what supplier data must be filed, and which documented procedures must exist on site.
The headline change—an exemption for certain foreign distributors—has prompted many international MedTech companies to consider cancelling their Canadian establishment licences. Cancelling without mapping every Canadian ship-to party is the expensive mistake. Replacement GUI-0016 (Guidance on medical device establishment licensing, issued June 17, 2026) states that distributors outside Canada that sell medical devices solely to an MDEL holder in Canada are exempt. Direct sales to a Canadian hospital, other health-care facility, health-care professional, first responder, or retailer still require an MDEL, because those buyers are not the ultimate consumer and typically do not themselves hold an establishment licence.
This operating guide is the keep-versus-cancel, supplier-list, documented-procedure, and fee map for SOR/2026-110 and GUI-0016. It is not a second Canada Medical Device Licence (MDL) 101, not a rewrite of the 2026 Terms and Conditions / REP / MLMD reform, and not a census of the MDALL product-licence listing. If GUI-0016 conflicts with the Food and Drugs Act or the Medical Devices Regulations (MDR), the Act and the regulations prevail.
Direct Answer: What Changed Under SOR/2026-110 and GUI-0016?
Section 10 of SOR/2026-110 states that the regulations come into force on the 180th day after the day on which they are registered. Registration was June 4, 2026. Health Canada's Medical Devices Compliance Program (MDCP) bulletin of June 17, 2026, replacement GUI-0016, and replacement FRM-0292 all label December 14, 2026 as the operational date and describe it as 180 days after Gazette Part II publication on June 17, 2026.
Until December 14, 2026, replacement GUI-0016 and FRM-0292 are labelled "for reference only". GUI-0016 version 10 (December 14, 2024) remains the in-force guidance. Do not cite the June 17, 2026 GUI-0016 text in a filing as if it were already in force.
| Date label | Calendar date | What it is | Source |
|---|---|---|---|
| Statutory coming-into-force formula | 180th day after June 4, 2026 registration (calendar arithmetic lands on December 1, 2026) | Section 10 of SOR/2026-110 as written | Canada Gazette Part II, SOR/2026-110 |
| Health Canada operational date | December 14, 2026 | Published go-live on GUI-0016, FRM-0292, and the MDCP bulletin (180 days after Gazette Part II publication June 17, 2026) | MDCP bulletin; GUI-0016 / FRM-0292 banners |
| In-force guidance today | Present through December 13, 2026 | GUI-0016 version 10 | Current GUI-0016 |
| First ALR that must carry the new supplier fields | Before April 1, 2027 | Section 46.1 annual licence review after coming into force | SOR/2026-110 s. 3 / MDR 46.1(1) |
Planning rule: Treat December 14, 2026 as Health Canada's published administrative go-live. Quote section 10 as written. Do not invent a third date, and do not collapse the two official labels.
The Three Core Pillars of MDEL Phase 2
- Foreign-distributor verification rewrite (new subsection 44(4)). After coming into force, subsection 44(3) (the duty to ensure the person you import from holds an establishment licence) does not apply to: (a) a person who imports a Class I medical device from the manufacturer of that device and who holds an establishment licence; (b) a person who imports a Class II, III or IV medical device from the manufacturer of that device; or (c) a person who imports any medical device from a person other than the manufacturer of that device and who holds an establishment licence. Paragraph (c) is the new Phase 2 rule. GUI-0016 (effective December 14, 2026) then states that distributors outside Canada that sell solely to an MDEL holder in Canada are exempt. Retailers and health-care facilities are not in new 44(4); they are already exempt from holding an MDEL under current subsection 44(2).
- Mandatory upstream supplier information (new 45(f.1) and 45(f.2), annual review 46.1, transitional section 9). Applicants and holders must provide the name and address of any person, other than the manufacturer, who sells a medical device to the establishment for importation or distribution, plus the classes of those devices. Updates travel with the annual licence review due before April 1. Health Canada stated in the Gazette that supplier information is confidential business information / Protected B and will not be posted like the public MDEL listing. Applications still under review on coming-into-force day cannot be issued until that information is provided.
- Explicit documented-procedure duties (52(3), 58, new 58.1, 59(3)–(4), 61.2(4), and 45(j) building addresses). The amendments make the duty to establish, implement, and maintain those procedures explicit. Health Canada stated in the Gazette that applicants do not submit the procedures for review with the MDEL application; they continue to identify the buildings where the procedures are in place. Paragraphs 45(g) to (i) (the old attestations) are repealed. New section 58.1 (handling, storage, delivery, installation, servicing, and corrective action) applies to Class II, III, or IV devices only.
Phase 2 does not repeal MDEL for Canadian importers, does not replace MDSAP or MDL for Class II–IV products, does not move MDEL filing onto the REP/CESG gateway, and does not change investigational, special-access, or custom-made devices under Parts 2 and 3 of the MDR.
Is MDEL Phase 2 a New Product Licence, or a Rewrite of Establishment Licensing?
International manufacturers routinely conflate the two Canadian licences:
- A Medical Device Licence (MDL) is a premarket product authorization under Part 1 (sections 26–43) of the MDR for Class II, III, and IV devices. It requires demonstrated safety and effectiveness and a valid MDSAP quality-management certificate. Class I devices do not receive an MDL. See the Health Canada device-licence 101.
- An MDEL is an establishment-level authorization under sections 44–51.1. It is issued to Class I manufacturers (who sell in Canada without an MDL), and to importers and distributors of all classes, unless an exemption in subsection 44(2) applies. It authorizes the activity of importing or distributing and is the hook for distribution records, complaint handling, recalls, and incident reporting.
| Regulatory dimension | Medical Device Licence (MDL) | Establishment licence (MDEL) |
|---|---|---|
| Governing MDR sections | 26–43 | 44–51.1 |
| What is authorized | A specific product / device | An establishment's commercial activity |
| Typical parties | Legal manufacturer | Importer, distributor, Class I manufacturer |
| Device classes | Class II, III, IV (Class I has no MDL) | Class I manufacturers; Class I–IV importers and distributors |
| Quality-system pre-requisite | MDSAP / ISO 13485 certificate | Documented procedures (not a second MDSAP certificate) |
| Public database | MDALL (product licences) | MDEL listing (establishments) |
| Impact of SOR/2026-110 | None (premarket unchanged) | Direct structural rewrite |
This is the missing Canada row in the site's five-jurisdiction economic-operator comparison. It is also a different 2026 instrument from the MLMD pre-market guidance.
What Did SOR/2026-110 Change in Subsection 44(4)?
Until Phase 2 comes into force, subsection 44(3) still requires any person who imports a medical device to ensure that the person from whom they import it holds an establishment licence. Current subsection 44(4) (SOR/2018-225) only carves out imports from the manufacturer: Class I imports from the manufacturer if the importer holds an MDEL, and Class II–IV imports from the manufacturer.
That structure is why a US master distributor or EU logistics hub selling to a Canadian importer, rather than the finished-device manufacturer selling directly, has been treated as needing its own MDEL. Health Canada's RIAS estimates the government will stop collecting about CAD $333,000 per year in foreign-distributor MDEL fees. That is a fee-collection estimate, not a headcount of foreign MDELs and not a per-company refund.
The New Statutory Text (SOR/2026-110, section 1)
SOR/2026-110 replaces subsection 44(4) with:
(4) Subsection (3) does not apply to
(a) a person who imports a Class I medical device from the manufacturer of that device and who holds an establishment licence;
(b) a person who imports a Class II, III or IV medical device from the manufacturer of that device; or
(c) a person who imports any medical device from a person other than the manufacturer of that device and who holds an establishment licence.
Paragraphs (a) and (b) preserve the manufacturer-import exceptions. Paragraph (c) is the Phase 2 addition: a Canadian MDEL holder who imports from an intermediary no longer has to verify that the intermediary holds an MDEL.
GUI-0016 (effective December 14, 2026) operationalizes that change: distributors outside Canada that sell medical devices solely to an MDEL holder in Canada are listed as exempt. That is guidance. The binding rule is new 44(4)(c) plus existing 44(1)–(3).
Who Is Exempt From Holding an MDEL (subsection 44(2), unchanged by SOR/2026-110)
Current subsection 44(1) prohibits importing or selling a medical device unless the person holds an establishment licence. Subsection 44(2) already exempts:
| 44(2) party | What the exemption covers | Phase 2 implication |
|---|---|---|
| (a) a retailer | Import or sale by a retailer | Still no MDEL to sell to the ultimate consumer. If the retailer imports, 44(3) still requires the foreign seller to hold an MDEL. |
| (b) a health-care facility | Import or sale by a hospital or other health-care facility | Still no MDEL to use devices on patients. If the facility imports, 44(3) still requires the foreign seller to hold an MDEL. |
| (c) Class II, III or IV manufacturer | Import or sale by the manufacturer of that licensed device | Still no MDEL for the manufacturer's own Class II–IV devices. An MDL remains required. If the same legal entity also imports someone else's devices, it needs an MDEL as importer. |
| (d) Class I manufacturer who imports or distributes solely through an MDEL holder | Class I manufacturer selling only through a licensed establishment | Matches GUI-0016: Class I manufacturers whose devices are solely distributed through another MDEL holder do not need their own MDEL. |
New 44(4) does not move retailers or health-care facilities into the foreign-distributor exemption. They were never in 44(4). Treating 44(4) as “retailer, hospital, or MDEL holder” is the wrong section.
The Hospital and Retailer Trap
GUI-0016 Table 2 (effective December 14, 2026) is the operational trap:
- Selling to hospitals, other health-care facilities, health-care professionals, or first responders requires an MDEL, because those parties are not the ultimate consumer.
- A hospital that imports devices for use on patients does not need an MDEL, but “the manufacturer of a Class I medical device or the Class I, II, III or IV medical device distributor from whom the hospital purchased the medical device must” hold one.
- A person outside Canada who sells to health-care facilities, retailers, or other persons in Canada who do not need an MDEL (other than the ultimate consumer) needs an MDEL.
- A person outside Canada who sells solely to importers in Canada that have an MDEL does not need an MDEL.
If a US or European distributor cancels its MDEL on December 14, 2026 and continues to drop-ship, tender, or invoice Canadian hospitals, other health-care facilities, or retail chains:
- The foreign distributor is selling into Canada without an establishment licence (44(1)), unless a 44(2) exemption actually fits the facts.
- The Canadian hospital or retailer that imports is in breach of 44(3), because they do not hold an MDEL and therefore do not get the new 44(4)(c) exception.
- Health Canada can inspect the establishment (FRM-0292) and may suspend an establishment licence under section 49 if the statutory grounds are met. Section 51.1 is not a “non-compliance notice” or border-hold power: it cancels a licence that has been suspended more than 12 months, or whose holder failed to submit the annual review required by 46.1(1). Investigational, special-access, and custom-made devices remain under Parts 2 and 3 of the MDR; this Part 1 rewrite does not change those pathways.
| Your role | Downstream Canadian customer | MDEL after December 14, 2026 |
|---|---|---|
| Foreign distributor | Canadian MDEL-holding importer only | Exempt (new 44(4)(c) + GUI-0016). May cancel or let the licence lapse once licensable activities have ceased. |
| Foreign distributor | Hospital / clinic / other health-care facility | Mandatory. Table 2 trap. |
| Foreign distributor | Retailer (pharmacy, optical, mass merchant) | Mandatory. Table 2 trap. |
| Foreign distributor | Ultimate consumer / end user only | Retailer exemption under 44(2)(a) / GUI-0016, if the facts are truly retail sales to the end user. Mixed hospital/retailer books kill the exemption. |
| Canadian importer | Any domestic customer | Mandatory. Phase 2 does not repeal importer MDEL. |
| Canadian domestic distributor | Hospital or retailer | Mandatory. |
| Class I manufacturer | Sells solely through a Canadian MDEL holder | Exempt under 44(2)(d). |
| Class I manufacturer | Sells direct into Canada (including to hospitals or retailers) | Mandatory. |
| Class II–IV manufacturer | Sells only its own licensed devices (holds MDL) | Exempt from MDEL under 44(2)(c). Still needs the MDL and MDSAP. |
Mandatory Supplier Lists: Sections 45(f.1), 45(f.2), and Annual Review
To keep supply-chain visibility after dropping duplicative foreign licences, SOR/2026-110 adds two application fields.
45(f.1): the name and address of any person, other than the manufacturer, who sells a medical device to the establishment for the purposes of importation or distribution.
45(f.2): for each person referred to in paragraph (f.1), other than the manufacturer, the classes of the devices that are being imported or distributed.
Finished-device manufacturers stay on the existing manufacturer fields in section 45 (including 45(d)). They are not listed on the new supplier rows. Do not cite repealed paragraphs 45(g) to (i) as the manufacturer-exclusion rule; those paragraphs are the old attestations, which SOR/2026-110 repeals.
| Data field | What SOR/2026-110 actually requires |
|---|---|
| Supplier legal name and address | 45(f.1): name and address of each non-manufacturer seller to the establishment |
| Device classes | 45(f.2): classes of the devices being imported or distributed from that person |
| Who is excluded from 45(f.1)/(f.2) | The manufacturer (the finished-device manufacturer is a different section 45 field) |
| When to file | Initial application; then with each annual review before April 1 (46.1(1)), including updates |
| Public or confidential | Gazette: confidential business information / Protected B; not the public MDEL listing |
Annual Licence Review (section 46.1)
Amended 46.1(1) requires every unsuspended MDEL holder to submit an application for review of their licence to the Minister before April 1 of each year, including the information and documents referred to in section 45 and any updates. That is how supplier-list changes enter the file. Section 48's 15-day notification duty still applies only to changes in 45(a) or (b) (establishment name/address and representative contact), not to 45(f.1) supplier rows.
Transitional applications (section 9(2))
A person who submitted an establishment-licence application under section 45 as it read before coming-into-force day, and in respect of which no decision has been made, must not be issued the licence unless, by that day and in the form established by the Minister, they provide the 45(f.1) and 45(f.2) information. Pending files on the old form need a supplier-data supplement before issuance.
Confidentiality
Industry asked whether supplier networks would be posted. Health Canada's Gazette response: supplier information is confidential business information under the Food and Drugs Act and treated as Protected B in Health Canada's internal database. A UDI system was raised in consultation and ruled out of scope for this package.
The Gazette RIAS, from Health Canada's own application files, reports an average of about 11 suppliers on an initial application and about two supplier updates per annual review, and that about one third of importers and distributors already provide supplier information voluntarily. Those are application-file averages, not a census of MDEL holders, not incidence of imported devices, and not a MedDeviceGuide recompute. Do not substitute MDALL product-licence counts for MDEL establishment counts.
Do You Upload Documented Procedures with FRM-0292?
No. A consultation comment assumed Phase 2 would require submitting procedure binders with the application or ALR. Health Canada's Gazette response:
The amendments do not introduce a requirement for MDEL holders/applicants to submit their documented procedures for review. The amendments eliminate the attestations for documented procedures. Applicants and holders will continue to provide a document that includes the address for the location where each safety management activity takes place.
That document is new 45(j): the address of each building where the procedures described in any of sections 52, 58, 58.1 and subsections 59(3) and (4) and 61.2(4) are in place. 45(j) is a building-address field, not a new SOP attestation checkbox. The old 45(g)–(i) attestations are repealed.
| MDR section after SOR/2026-110 | Procedure subject | Who the amending text actually names | Do not confuse with |
|---|---|---|---|
| 52(3) | Documented procedures for maintaining distribution records | Manufacturer, importer, and distributor of a medical device | The distribution-record keeping duty in 52(1), which already existed |
| 58 | Documented procedures that enable complaint handling and recall | Manufacturer, importer, and distributor of a medical device | Already an explicit procedure section; the chapeau is rewritten to “establish, implement and maintain” |
| 58.1 (new) | Handling, storage, delivery, installation, servicing, and corrective action, as applicable | Manufacturer, importer, and distributor of a Class II, III or IV medical device | Not a Class I mandate |
| 59(3) | Documented procedures for making the preliminary and final reports in 59(1) and (1.1) | Manufacturer and importer of a Class I medical device | The 10-day / 30-day clocks live in section 60, not in 59(3) |
| 59(4) | Documented procedures for making the preliminary and final reports in 59(1) | Manufacturer and importer of a Class II, III or IV medical device | Distributors are not named in 59(3) or 59(4) |
| 61.2(4) | Documented procedures for timely provision of 61.2(2) serious-risk information | Holder of a medical device licence and the importer of a Class II, III or IV medical device | The 72-hour clock is 61.2(3), and it does not apply to every MDEL holder |
The Class I section 58.1 carve-out
New 58.1 is limited to Class II, III, or IV devices. Gazette consultation text is explicit that Class I manufacturers, importers, and distributors are not currently required to establish handling/storage/delivery/installation/servicing/corrective-action procedures, and imposing 58.1 on Class I would have been incremental. Class I parties still need distribution-record, complaint/recall, and (for manufacturers and importers) incident-reporting procedures.
MDSAP and ISO 13485 alignment
The RIAS states that Class II–IV manufacturers already establish, implement, and maintain documented procedures as part of MDSAP certification, which satisfies CAN/CSA-ISO 13485:2016, so making those manufacturers subject to the explicit procedure provisions is not treated as incremental cost. Section 58.1 is not a second QMS certificate and is not a replacement for where MDSAP is mandatory. Domestic importers and distributors who sit outside MDSAP are the parties for whom the explicit text is new operational work.
Health Canada does not prescribe SOP format. Inspections, not FRM-0292 screening, are where procedures are tested.
Date-Label Split: Statutory Registration vs. Health Canada Operational Date
Two official clocks are on the page at once. Quote both; follow Health Canada's published December 14, 2026 date for ERP cutovers, form switches, and cancellations.
| Paradigm | Date | Authority |
|---|---|---|
| Statutory formula | 180th day after registration on June 4, 2026 | SOR/2026-110 section 10 |
| Published administrative go-live | December 14, 2026 | GUI-0016 banner, FRM-0292 banner, MDCP bulletin (“180 days after being published in the Canada Gazette, Part II on June 17, 2026”) |
| In-force guidance until go-live | GUI-0016 version 10 (December 14, 2024) | Current GUI-0016 URL |
| Replacement texts | Reference only until December 14, 2026 | Same banners |
The December 1 versus December 14 split is unresolved on the face of the two official sources. Do not invent a reconciliation date. In filings before December 14, 2026, cite version 10. In planning documents, cite December 14, 2026 as Health Canada's operational threshold and quote section 10.
Health Canada Fee Structure (2026–2027)
There is no separate Phase 2 tariff. Establishment licensing is cost-recovered under the Fees in Respect of Drugs and Medical Devices Order. The official fee table on Health Canada's fees page, for fiscal year April 1, 2026 through March 31, 2027:
| Transaction | Official government fee (source basis) | Notes |
|---|---|---|
| MDEL application for a new licence (2026–2027) | CAD $5,519 | Same line as annual review. 2025–2026 was $5,426. |
| Annual licence review | CAD $5,519 | Invoiced; FRM-0292: invoice follows screening. |
| Small-business remission (25%) | Arithmetic net CAD $4,139.25 if status is already granted | 25% of $5,519. Not a separate published line. |
| Notification, amendment, or cancellation | CAD $0 | FRM-0292: “There are no fees for notifications, amendments or to cancel your licence.” |
| Class II–IV MDL right-to-sell | CAD $460 (2026–2027; $452 in 2025–2026) | Separate product fee. Not an MDEL tariff. |
| Provider SOP writing / supplier-list compilation | Not a government fee | Internal or consultant cost. |
Unpaid MDEL fees: FRM-0292 states Health Canada may withhold services, and time while services are withheld does not count toward the 120 calendar day service standard.
The Canada device-licence 101 now points at this official $5,519 line for 2026–2027. Do not reuse older single-class / multiple-class MDEL tables.
Small-business fee mitigation
Qualifying small businesses receive a 25% reduction on establishment-licence fees. The legal definition is in subsection 1(1) of the Fees Order (SOR/2019-124), including affiliates:
- fewer than 100 employees in total, or
- gross revenue of $30,000 or more but less than $5 million.
You must apply for and receive small-business status before filing the MDEL application or ALR. FRM-0292: if you are not registered when you file, you are charged the full fee. First-time pre-market (MDL) 100% remission is a different line; do not treat an MDEL ALR as a free first submission.
RIAS costing — what the numbers are not
| RIAS figure | What Health Canada published | What it is not |
|---|---|---|
| ~$333,000 per year | Foreign-distributor MDEL fees Health Canada expects to stop collecting / foreign holders expect to stop paying | A per-company refund; a headcount; standing in the cost-benefit analysis (foreign-company impacts are acknowledged but excluded) |
| $1.8 million PV over 10 years | Total monetized costs of the amendments | A “net saving” that offsets streamlining |
| $2.3 million PV over 10 years | Benefit to foreign MDEL holders | Included as a CBA benefit (no standing) |
| ~11 suppliers / ~2 annual updates | Application-file averages | Incidence, a census, or a MedDeviceGuide recompute |
30/60/90-Day Keep-or-Cancel Implementation Roadmap
Between publication of this article (September 1, 2026) and Health Canada's December 14, 2026 operational date:
| Window | Dates | Work that actually changes the keep/cancel decision |
|---|---|---|
| Days 1–30 | September 1 – September 30, 2026 | Map 24-month Canadian ship-to accounts: MDEL-holding importers vs hospitals/health-care facilities vs retailers vs true end users. Flag any foreign MDEL that still ships to a non-MDEL buyer as cannot cancel. Verify counterparties on the MDEL listing. |
| Days 31–60 | October 1 – October 31, 2026 | Canadian importers: compile 45(f.1)/(f.2) name, address, and class rows for non-manufacturer suppliers. Audit procedures against 52(3), 58, 58.1 (Class II–IV only), 59(3)–(4), and 61.2(4). List 45(j) building addresses. If eligible, obtain small-business status before the next fee-bearing filing. |
| Days 61–90+ | November 1 – December 14, 2026 | Qualifying foreign distributors: prepare FRM-0292 Appendix A for the date licensable activities have ceased, not as a paper cancellation while hospital POs continue. Pending applications: file 45(f.1)/(f.2) data so section 9(2) does not block issuance. On December 14, switch to replacement GUI-0016 and FRM-0292. Calendar the April 1, 2027 ALR. |
Do not mail SOP binders with FRM-0292. Do not cite replacement GUI-0016 as in-force guidance before December 14, 2026.
What Fails: Common Operational Traps
| Failure mode | Root misconception | What the official text actually does |
|---|---|---|
| Cancel a foreign MDEL while still selling to hospitals or retailers | “Phase 2 voids every foreign MDEL on December 14” | GUI-0016 Table 2 still requires an MDEL for those buyers. 44(4)(c) helps only when the Canadian buyer holds an MDEL. |
| Cite replacement GUI-0016 in a filing before December 14, 2026 | “Published June 17 means in force June 17” | Both replacement pages are reference-only until December 14. Version 10 remains the in-force guidance. |
| Upload SOP binders with FRM-0292 | “Phase 2 is a document review of procedures” | Gazette: procedures are not submitted for review. 45(j) is building addresses. 45(g)–(i) attestations are repealed. |
| Impose 58.1 handling/servicing procedures on a Class I-only importer | “All MDEL holders got a new warehouse SOP mandate” | 58.1 is Class II, III, or IV only. |
| Treat an incomplete supplier list as a section 51.1 “suspension” | “Miss a field, lose the licence the same day” | 51.1 cancels a licence after a >12-month suspension, or if the holder fails to submit the 46.1(1) annual review. Missing 45(f.1) data on a pending new application blocks issuance under transitional section 9(2). |
| Count MDALL rows as MDEL holders | “Canada has one device database” | MDALL is product licences. MDEL listing is establishments. Supplier lists are Protected B. |
| Treat $333,000 or 11 suppliers as your company's saving or as incidence | “RIAS numbers are a census” | Fee-collection and application-file estimates, with the limits above. |
Frequently Asked Questions (FAQs)
Can a foreign distributor cancel its MDEL on December 14, 2026 if it sells only to a Canadian importer that holds an MDEL?
Yes, once those are the facts and licensable activities have ceased. New 44(4)(c) stops requiring the Canadian MDEL holder to verify that the upstream non-manufacturer holds an MDEL. GUI-0016 (effective December 14, 2026) lists distributors outside Canada that sell solely to an MDEL holder in Canada as exempt. FRM-0292 Appendix A is the cancellation path; there is no cancellation fee. The Canadian importer must be ready to file 45(f.1)/(f.2) supplier rows.
If we sell directly to Canadian hospitals or retailers, do we still need an MDEL after Phase 2?
Yes. Hospitals, other health-care facilities, and retailers are exempt from holding an MDEL under subsection 44(2), not under new 44(4). Because they do not hold an establishment licence, 44(4)(c) does not apply when they import. GUI-0016 Table 2 still requires an MDEL for sales to those parties.
Is GUI-0016 issued June 17, 2026 already in force on September 1, 2026?
No. The replacement GUI-0016 and FRM-0292 banners say they are for reference only until December 14, 2026. GUI-0016 version 10 remains the in-force guidance. GUI-0016 is guidance in any event: if it conflicts with the Act or the MDR, the Act and regulations prevail.
Do we have to attach our complaint, recall, and distribution-record SOPs to the MDEL application?
No. Health Canada does not require SOP uploads with FRM-0292. Provide 45(j) building addresses. Inspections test whether the procedures exist and work.
What is the Health Canada MDEL fee for 2026–2027, and is there a small-business rate?
The official 2026–2027 fee for a new MDEL application and for annual review is CAD $5,519 (Health Canada fees page; effective April 1, 2026). Qualifying small businesses that already hold status receive a 25% establishment-licence remission (Fees Order definition: fewer than 100 employees including affiliates, or gross revenue of $30,000 or more but less than $5 million). Notifications, amendments, and cancellations have no government fee.
Is the MDEL listing the same public file as MDALL?
No. The MDEL listing is the establishment register. MDALL is the Class II–IV product-licence listing. Class I devices and Protected B supplier lists do not appear on MDALL.
How Pure Global Supports Canadian Market Access and Establishment Licensing
Navigating Health Canada's MDEL Phase 2 keep-or-cancel decision, supplier-list filings, and Annual Licence Reviews alongside mandatory digital REP submissions and 2026 Terms and Conditions / MLMD reforms is a coordinated regulatory and quality-system problem.
Pure Global provides regulatory consulting, QMS engineering, and compliance management for medical technology companies entering or remaining in Canada.
- Canadian market access and MDEL strategy: keep-or-cancel distribution maps, section 45(f.1) supplier data, ALR packages, and small-business fee filings via the Canada market practice.
- Class I–IV product licensing and REP submissions: MDL dossiers and CESG/REP transactions for Class II–IV devices.
- Procedure gap assessments: distribution records (section 52), complaints/recalls (section 58), Class II–IV handling/storage (section 58.1), and incident-reporting procedures (section 59)—implemented on site, not mailed with FRM-0292.
- In-country representation across other jurisdictions where a local establishment or authorized representative is required.
To audit a Canadian distribution structure or prepare the next Annual Licence Review, contact Pure Global.
Pure Global provides independent regulatory affairs, quality systems, and market-access advisory services. Pure Global is not Health Canada, does not issue Medical Device Licences (MDL) or Establishment Licences (MDEL), and is not a Canadian regulatory authority.
Sources and Regulatory References
- Regulations Amending the Medical Devices Regulations (Establishment Licences): SOR/2026-110 — Canada Gazette, Part II, Volume 160, Number 12 (Registered June 4, 2026; Published June 17, 2026), including the Regulatory Impact Analysis Statement.
- Guidance on medical device establishment licensing (GUI-0016) (effective December 14, 2026) — Health Canada, Medical Devices Compliance Program (Issued June 17, 2026; reference-only until the effective date).
- Guidance on medical device establishment licensing (GUI-0016) — Version 10 — Health Canada (in-force guidance through December 13, 2026).
- Medical Device Establishment Licence (MDEL) application: instructions (FRM-0292) (effective December 14, 2026) — Health Canada.
- Phase 2 of our work to modernize medical device establishment licensing — Health Canada MDCP bulletin (June 17, 2026).
- Fees for Health Canada — Medical device establishment licence fee — Health Canada (2026–2027: application and annual review CAD $5,519).
- Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124) — small-business definition, subsection 1(1).
- Medical Devices Establishment Licence (MDEL) Listing — Health Canada public establishment register.
- Medical Devices Regulations (SOR/98-282) — including current subsections 44(1)–(4), 46.1, 49, 51.1, 59, 60, and 61.2 (consolidated text current to 2026-06-21; Phase 2 amendments come into force on the section 10 clock).
- Food and Drugs Act (R.S.C., 1985, c. F-27).
- Medical Devices Active Licence Listing (MDALL) — product-licence database, not the MDEL listing.
- Health Canada Medical Device License Guide.
- Health Canada Regulatory Reform 2026 Guide.
- Health Canada REP and CESG Mandatory Digital Submissions Guide.
- Medical Device Economic Operator Obligations Compared.
- Canada MDALL Class III/IV Device Concentration Analysis.
- MDSAP Audit Guide.
- Health Canada MLMD Pre-market Guidance 2026.